Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539558 | 0.83 | HTR2A (0.38) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL12693532 | 0.80 | MAP3K14 (0.41) | PIK3CAPIK3CDPIK3CGMAP3K14 | |
| SCHEMBL18827236 | 0.76 | PIK3CD (0.50) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485055 | 0.72 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL1485581 | 0.69 | PIK3CA (0.43) | PIK3CAPIK3CDMAP3K14 | |
| SCHEMBL1485431 | 0.69 | PIK3CA (0.39) | PIK3CAPIK3CDPIK3CGMAP3K14 | |
| SCHEMBL19594175 | 0.67 | MAP3K14 (0.44) | PIK3CDMAP3K14 | |
| SCHEMBL12693206 | 0.67 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3CGMAP3K14 | |
| SCHEMBL1485608 | 0.67 | MAP3K5 (0.39) | PIK3CAPIK3CDPIK3CGMAP3K14 | |
| SCHEMBL21583996 | 0.66 | MAP3K5 (0.39) | PIK3CAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9090628-B2 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | GENENTECH, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2012126901-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R4 | PIK3CA 1/4885PIK3CD 2/4885PIK3CG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.